ArticleImmunotherapy2024

Avoided recurrences and costs with adjuvant atezolizumab for patients with early non-small cell lung cancer in Europe.

Alastair Greystoke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.